Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis In Line For Ofatumumab MS Approval In June

Will Rival Roche's Ocrevus

Executive Summary

Novartis’s cancer drug has now been filed for multiple sclerosis in the US, armed with a priority review, and in Europe.

You may also be interested in...



Keeping Track: Two Novel Migraine Drugs Highlight Busy Week For US FDA Approvals

The latest drug development news and highlights from our US FDA Performance Tracker.

Potential Cardiovascular Blockbuster Inclisiran Among New Filings At EMA

The European Medicines Agency has agreed to review pan-EU marketing applications for a number of new medicines.

Novartis MS Drug Mayzent Gets Europe OK

Mayzent is the first oral treatment specifically indicated for patients with secondary-progressive multiple sclerosis and while it is expected to be a blockbuster, the company tells Scrip that educational programs for physicians are a priority.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC141714

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel